Navigation Links
BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
Date:3/3/2008

BOSTON/Massachusetts, TORONTO/Canada, March 3 /PRNewswire/ - BIKAM, pioneers in the discovery and development of potential therapeutic agents for the treatment of degenerative eye diseases and ocular disorders and Dalton Medicinal Chemistry, have jointly announced an exclusive worldwide collaboration and agreement to discover and develop new therapeutics for unmet needs in ophthalmology.

Dalton Medicinal Chemistry will utilize their proprietary insights to advance several novel classes of compounds against selected BIKAM targets. BIKAM will advance these agents with their cutting edge battery of biological assays and delivery methodologies.

David Garvey, VP, Chemistry at BIKAM commented: "We are pleased to have the opportunity to work with the creative team at Dalton Medicinal Chemistry in the discovery and development of new entities for treating eye diseases. Their expertise, together with our propriety and leading position will quickly deliver important new medicines."

Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We are delighted to have this opportunity to work with BIKAM in the discovery and development of much needed agents to treat these debilitating diseases".

About BIKAM

BIKAM, Inc., is a biopharmaceutical company focused on the development of novel therapeutics for the treatment of degenerative eye diseases and disorders. BIKAM is building a portfolio of product candidates based on patented technologies that were identified at the University of Florida, Gainesville. BIKAM investors include HealthCare Ventures, CHL Medical Partners and Fidelity Biosciences.

About Dalton Pharma Services & Dalton Medicinal Chemistry

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada contract pharmaceutical manufacturer that supplies chemistry and analytical services to the biotechnology and pharmaceutical industries in the areas of chemistry and fine chemical manufacture. Dal
'/>"/>

SOURCE Dalton Pharma Services
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
2. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
3. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
4. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
5. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
6. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
7. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
8. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
9. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
10. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
11. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... ISN has released its third annual U.S. ... series. With data aggregated from over eight billion U.S. ... online contractor management platform, ISNetworld, this three-part series provides ... The Contractor Performance Benchmarking ... in two industry specific volumes: Oil & Gas, ...
(Date:12/17/2014)... Houston, TX (PRWEB) December 17, 2014 ... marketing and administration for Stoller Group. In this position, ... Stoller Group, on administrative matters, develop marketing strategy and ... and services. , “Achim has tremendous knowledge and ... president of Stoller Group. “His experience and innovative thinking ...
(Date:12/17/2014)... December 17, 2014 Gene synthesis ... it has entered into a technology access and ... to apply DNA2.0’s proprietary protein engineering technology, known ... , “We are extremely excited that the global ... This proprietary bioengineering technology has now been ...
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat Pharma, ... 2 study evaluating the investigational oral NK-1 receptor ... with severe, chronic itch who are unresponsive or ... including topical steroids and antihistamines. ... Visual Analog Scale (VAS) itch score from baseline, ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... Minimal Effect on Heart Rhythm ... Changes in Schizophrenia Patients, VIENNA, Austria, Oct. 17 ... Organon -- is effective,in treating acute manic episodes associated with bipolar ... this week at,the 20th European College of Neuropsychopharmacology (ECNP) Congress. ...
... PRINCETON, N.J., Oct. 16 Bristol-Myers Squibb,Company (NYSE: ... Food and Drug,Administration (FDA) has granted approval of ... with metastatic or locally,advanced breast cancer in patients ... and capecitabine. The FDA has also granted,approval of ...
... Management Team, ROCKVILLE, Md., Oct. 16 ... company developing,therapeutics for the treatment of cancer and ... has been appointed its Senior Vice,President, Research and ... officer of EntreMed by the Board of Directors, ...
Cached Biology Technology:Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 2Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 3Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 4Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 5Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 6FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 2FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 3FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 4FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 5FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 6FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer 7EntreMed Appoints Senior Vice President of Research and Development 2EntreMed Appoints Senior Vice President of Research and Development 3EntreMed Appoints Senior Vice President of Research and Development 4
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... More than 500 million years ago, single-celled organisms ... that ultimately became plants and animals. Just how ... evolutionary biologists. But scientists in the University ... that key step in the laboratory using natural ...
... German . The most effective anti-malaria drug ... means that it will be possible to provide medication for ... affordable price. Researchers at the Max Planck Institute of Colloids ... developed a very simple process for the synthesis of artemisinin, ...
... co-development partnership with the American Society of Gene & ... be included in the Springer series Advances in Experimental ... edited volumes per year in the field of gene ... for the books and Springer will handle production, marketing, ...
Cached Biology News:University of Minnesota biologists replicate key evolutionary step 2University of Minnesota biologists replicate key evolutionary step 3University of Minnesota biologists replicate key evolutionary step 4Anti-malaria drug synthesized with the help of oxygen and light 2Anti-malaria drug synthesized with the help of oxygen and light 3
Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Antigen: Synthetic peptide corresponding to...
Polyclonal Antibody to TRIB1/ SKIP1/ Tribbles 1...
TNF-Related Apoptosis Inducing Ligand-Receptor-1...
PMA (YPMA-1)...
Biology Products: